Keith Baggerly
Overview
Explore the profile of Keith Baggerly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
3900
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee S, Bondaruk J, Wang Y, Chen H, Lee J, Majewski T, et al.
Cell Rep
. 2024 Apr;
43(5):114146.
PMID: 38676926
We describe a strategy that combines histologic and molecular mapping that permits interrogation of the chronology of changes associated with cancer development on a whole-organ scale. Using this approach, we...
2.
Herbrich S, Baran N, Cai T, Weng C, Aitken M, Post S, et al.
J Immunother Cancer
. 2021 Jul;
9(7).
PMID: 34326171
Background: Acute myeloid leukemia (AML) stem cells (LSCs) are capable of surviving current standard chemotherapy and are the likely source of deadly, relapsed disease. While stem cell transplant serves as...
3.
Nagaraja A, Dood R, Armaiz-Pena G, Kang Y, Wu S, Allen J, et al.
JCI Insight
. 2021 Apr;
6(7).
PMID: 33793425
No abstract available.
4.
Siedel J, Ring K, Hu W, Dood R, Wang Y, Baggerly K, et al.
Gynecol Oncol
. 2021 Feb;
160(3):777-785.
PMID: 33563487
Background: Homologous recombination deficiency (HRD) score is related to chemotherapy response in some cancers, but its role in endometrial cancer in not known. We determined frequency and clinical significance of...
5.
Wen Y, Wang Y, Chelariu-Raicu A, Stur E, Liu Y, Corvigno S, et al.
Mol Cancer Ther
. 2020 Aug;
19(9):1943-1954.
PMID: 32737156
Abnormal activity of human prolactin (PRL) and its membrane-associated receptor (PRLR) contributes to the progression of uterine carcinoma. However, the underlying mechanisms are not well understood, and current means of...
6.
Guo C, Majewski T, Zhang L, Yao H, Bondaruk J, Wang Y, et al.
Cell Rep
. 2019 May;
27(6):1781-1793.e4.
PMID: 31067463
Sarcomatoid urothelial bladder cancer (SARC) displays a high propensity for distant metastasis and is associated with short survival. We report a comprehensive genomic analysis of 28 cases of SARC and...
7.
Ragon B, Odenike O, Baer M, Stock W, Borthakur G, Patel K, et al.
Clin Lymphoma Myeloma Leuk
. 2019 May;
19(7):431-440.e13.
PMID: 31056348
Background: With proven single-agent activity and favorable toxicity profile of MEK-1/2 inhibition in advanced leukemia, investigation into combination strategies to overcome proposed resistance pathways is warranted. Resistance to MEK inhibition...
8.
Simmons A, Fourkala E, Gentry-Maharaj A, Ryan A, Sutton M, Baggerly K, et al.
Cancer Prev Res (Phila)
. 2019 Apr;
12(6):391-400.
PMID: 30967390
Early detection of ovarian cancer has the potential to impact mortality. A multimodal screening strategy where rising CA125 values over time, analyzed with the risk of ovarian cancer algorithm (ROCA),...
9.
Majewski T, Yao H, Bondaruk J, Chung W, Lee S, Lee J, et al.
Cell Rep
. 2019 Feb;
26(8):2241-2256.e4.
PMID: 30784602
We used whole-organ mapping to study the locoregional molecular changes in a human bladder containing multifocal cancer. Widespread DNA methylation changes were identified in the entire mucosa, representing the initial...
10.
Villar-Prados A, Wu S, Court K, Ma S, LaFargue C, Chowdhury M, et al.
Mol Cancer Ther
. 2018 Nov;
18(2):421-436.
PMID: 30420565
Systematic approaches for accurate repurposing of targeted therapies are needed. We developed and aimed to biologically validate our therapy predicting tool (TPT) for the repurposing of targeted therapies for specific...